Johnson & Johnson provides substantive risk factor disclosures spanning operational, regulatory, and environmental domains. JNJ explicitly flags climate-related physical risks—including earthquakes, wildfires, flooding, and water scarcity—as potential disruptors to its facilities and supply chain, alongside the prospect of more stringent greenhouse-gas regulations increasing costs [JNJ:S0]. JNJ also discloses manufacturing concentration risk across 63 facilities and thousands of global suppliers [JNJ:S3], counterfeiting threats to product integrity and revenues [JNJ:S2], and anti-corruption regulatory exposure under the FCPA and laws in various other jurisdictions [JNJ:S4]. A fully balanced side-by-side comparison with Pfizer is constrained by the evidence retrieved: the PFE excerpts available for this analysis derive largely from interim filings that cross-reference the full 10-K risk factors section rather than reproducing substantive content [PFE:S0, PFE:S2, PFE:S3, PFE:S4], with only a brief passage on foreign-exchange sensitivity offering any analytical detail [PFE:S1]. It should be noted that Pfizer's annual 10-K does contain substantive risk disclosures—covering areas such as product recalls, manufacturing risks, nitrosamines, and COVID-19-related products—but those sections were not retrieved in the evidence set underlying this comparison, so no direct content-level assessment of Pfizer's risk profile can be made here.
JNJ: JNJ's risk factor disclosures are wide-ranging and specific, addressing climate-driven physical hazards and potential regulatory tightening on emissions [JNJ:S0], supply-chain vulnerabilities across 63 manufacturing facilities and thousands of suppliers [JNJ:S3], and product-integrity threats from counterfeiting [JNJ:S2]. Anti-corruption compliance risk under the FCPA and related multi-jurisdictional laws rounds out a disclosure profile that reflects a large, globally diversified healthcare company managing complex operational and regulatory exposures [JNJ:S4].
PFE: Based on the evidence retrieved, Pfizer's risk factor content cannot be meaningfully assessed. The available excerpts—drawn primarily from interim filings—consist largely of boilerplate cross-references to the full annual 10-K risk factors section [PFE:S0, PFE:S2, PFE:S3, PFE:S4], with only foreign-exchange sensitivity touched upon in any substantive way [PFE:S1]. This does not indicate an absence of robust risk disclosures in Pfizer's actual 10-K; rather, the relevant sections of that filing were not captured in the retrieved evidence.